Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc. Show more
42127 Pleasant Forest Court, Ashburn, VA, 20148-7349, United States
Market Cap
12.66M
52 Wk Range
$5.01 - $41.80
Previous Close
$6.06
Open
$5.85
Volume
59,520
Day Range
$5.85 - $7.10
Enterprise Value
-7.815M
Cash
18.75M
Avg Qtr Burn
-5.035M
Insider Ownership
6.82%
Institutional Own.
-
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
QRX003 Details Netherton syndrome | Phase 3 Data readout | |
QRX003 Details Pediatric Netherton Syndrome (NS) | Phase 1/2 Update | |
QRX003 Details Pediatric Peeling skin syndrome | IND Submission |
